Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Fate Therapeutics, Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
IPO Date: October 1, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $132.97M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.58 | 3.52%
Avg Daily Range (30 D): $0.07 | 5.89%
Avg Daily Range (90 D): $0.06 | 5.57%
Institutional Daily Volume
Avg Daily Volume: .85M
Avg Daily Volume (30 D): 1.69M
Avg Daily Volume (90 D): 1.83M
Trade Size
Avg Trade Size (Sh.): 108
Avg Trade Size (Sh.) (30 D): 275
Avg Trade Size (Sh.) (90 D): 298
Institutional Trades
Total Inst.Trades: 3,464
Avg Inst. Trade: $2.74M
Avg Inst. Trade (30 D): $.85M
Avg Inst. Trade (90 D): $1.64M
Avg Inst. Trade Volume: .13M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $3.83M
Avg Closing Trade (30 D): $.64M
Avg Closing Trade (90 D): $.64M
Avg Closing Volume: 204.45K
       
News
May 28, 2025 @ 9:54 PM
Fate Therapeutics Announces Phase 1 Data Presentat...
Source: N/A
Apr 2, 2025 @ 8:01 PM
Fate Therapeutics Reports New Employee Inducement ...
Source: N/A
Feb 28, 2025 @ 6:00 PM
NK Cell Therapy Market on Track for Exponential Gr...
Source: Delveinsight
Nov 29, 2024 @ 6:05 PM
Fate Therapeutics Announces Leadership Transition
Source: N/A
Nov 9, 2024 @ 6:30 PM
Fate Therapeutics Highlights Cancer-selective, HER...
Source: N/A
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-1.5 $-.32 $-.45
Diluted EPS $-1.5 $-.32 $-.45
Revenue $ 13.34M $ 1.63M $ 1.86M
Gross Profit $ $ $
Net Income / Loss $ -175.88M $ -37.62M $ -52.15M
Operating Income / Loss $ -200.49M $ -41.28M $ -61.75M
Cost of Revenue $ $ $
Net Cash Flow $ -90.22M $ M $ -1.85M
PE Ratio